 NEW YORK, Sept. 09, 2021 GLOBE NEWSWIRE -- BeyondSpring the Company or BeyondSpring NASDAQ: BYSI, a global pharmaceutical company focused on the development of cancer therapeutics, today announced three poster presentations of new data supporting the combination of plinabulin and G-CSF for the prevention of chemotherapy-induced neutropenia CIN at the European Society for Medical Oncology 2021 Congress taking place virtually September 16-21, 2021. Plinabulin in combination with G-CSF is currently under U.S. and China regulatory review with an FDA PDUFA date of November 30, 2021. The posters will become available on September 16, 2021 at 8:30 AM CEST and will remain available throughout the entire duration of the Congress. 